|  |
| --- |
| **Table S1: Baseline characteristics of PROSPER cohorts by treatment allocation - full cohort & Scottish cohort** |

|  | ***Full Cohort*** | ***Scottish Cohort*** |
| --- | --- | --- |
|  | ***Placebo*** | ***Pravastatin*** | ***Placebo*** | ***Pravastatin*** |
|  | ***(n = 2913)*** | ***(n = 2891)*** | ***(n = 1260)*** | ***(n = 1260)*** |
| **Continuous variates [mean (SD)]** |  |  |  |  |
| Age (years) | 75·3 (3·4) | 75·4 (3·3) | 75·3 (3·4) | 75·4 (3·4) |
| Systolic Blood Pressure (mmHg) | 155 (22) | 155 (22) | 154 (22) | 153 (21) |
| Diastolic Blood Pressure (mmHg) | 84 (12) | 84 (11) | 83 (11) | 83 (11) |
| Height (m) | 1·7 (0·1) | 1·7 (0·1) | 1·6 (0·1) | 1·6 (0·1) |
| Weight (kg) | 73·4 (13·5) | 73·4 (13·3) | 71·4 (12·9) | 72·3 (13·3) |
| Body Mass Index (kg/m) | 26·8 (4·3) | 26·8 (4·1) | 26·7 (4·2) | 26·8 (4·2) |
| Total cholesterol (mmol/L) | 5·7 (0·9) | 5·7 (0·9) | 5·7 (0·9) | 5·7 (1·0) |
| LDL cholesterol (mmol/L) | 3·8 (0·8) | 3·8 (0·8) | 3·8 (0·8) | 3·8 (0·8) |
| HDL cholesterol (mmol/L) | 1·3 (0·3) | 1·3 (0·4) | 1·3 (0·4) | 1·3 (0·4) |
| Triglycerides (mmol/L) | 1·5 (0·7) | 1·5 (0·7) | 1·6 (0·7) | 1·6 (0·7) |
| **Categorical variates [n ( %)]** |  |  |  |  |
| Men | 1408 (48%) | 1396 (48%) | 603 (48%) | 634 (50%) |
| Current smoker | 805 (28%) | 753 (26%) | 353 (28%) | 355 (28%) |
| Medical History |  |  |  |  |
|  | -Diabetes | 320 (11%) | 303 (10%) | 112 (9%) | 101 (8%) |
|  | -Hypertension | 1793 (62%) | 1799 (62%) | 722 (57%) | 724 (57%) |
|  | -Vascular disease | 1259 (43%) | 1306 (45%) | 618 (49%) | 621 (49%) |
|  |  | -Peripheral vascular disease | 311 (11%) | 338 (12%) | 155 (12%) | 168 (13%) |
|  |  | -Coronary heart disease | 916 (31%) | 965 (33%) | 473 (38%) | 477 (38%) |
|  |  | -Cerebrovascular disease | 324 (11%) | 331 (11%) | 135 (11%) | 131 (10%) |